Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Want to save on gas expenses? Check out our recommended credit cards that provide great benefits for fuel purchases.
21,732 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
CytomX Therapeutics delivered a sharp rally after promising Phase 1 data for its colorectal cancer program. This arti...
A tiny insider sale can spark big questions. This article explains what’s behind $211,680 sale, how Vicor’s AI-led de...
A look at how a $1,000 stake in McDonald’s versus Starbucks would have evolved over the past decade, with today’s mar...
TIAA’s CEO argues that leaders should rent the title, not own it, and invest in character traits that endure beyond a...
Investor Kevin O’Leary warns that bringing a parent to a job interview signals a loss of independence, insisting that...
Mining stocks are delivering outsized gains in a fresh gold rally, outpacing bullion as risk assets rebound and infla...
Bitcoin flirted with $76,000 as long-dormant coins linger. The Coin Days Destroyed Multiple hit a 2022-era low, fueli...
Turning 65 brings decisions about Social Security and Medicare. This guide breaks down three essential facts to help ...
Iraq restarts crude shipments via the Iraq-Turkey pipeline, nudging global oil prices lower as traders reassess suppl...
JEPQ offers monthly income via a covered-call strategy, but five-year performance trails uncapped NASDAQ exposure. Th...
Benchmark lowered its Bakkt price target by about 47%, arguing that near-term monetization remains elusive as the com...